Affordable Access

deepdyve-link
Publisher Website

The Evolving Role of Brentuximab Vedotin in Classical Hodgkin Lymphoma.

Authors
  • Lai, Catherine1
  • Kandahari, Adrese Michael1
  • Ujjani, Chaitra2
  • 1 Lombardi Comprehensive Cancer Center, Medstar Georgetown University Hospital, Washington, DC, USA.
  • 2 Seattle Cancer Care Alliance, Fred Hutchinson CRC, University of Washington, Seattle, WA, USA.
Type
Published Article
Journal
Blood and lymphatic cancer : targets and therapy
Publication Date
Jan 01, 2019
Volume
9
Pages
63–71
Identifiers
DOI: 10.2147/BLCTT.S231821
PMID: 31849558
Source
Medline
Keywords
Language
English
License
Unknown

Abstract

The arrival of the CD30 directed antibody-drug conjugate, brentuximab vedotin (BV), has altered the approach to patients with classical Hodgkin lymphoma. Since initial approval in 2011, BV has been extensively studied in previously untreated and relapsed/refractory patients. Treatment indications for the antibody-drug conjugate have been expanded from the previously treated population to include maintenance therapy after autologous stem cell transplantation and recently, combination with chemotherapy in newly diagnosed advanced stage patients. This article will review the evolution of BV in classical Hodgkin lymphoma, detailing the studies that led to the approved indications and discussion of recent trials in combination with chemotherapy and immunotherapy. © 2019 Lai et al.

Report this publication

Statistics

Seen <100 times